Lerdelimumab
Based on 1 Customer Validation
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research.
For research use only. We do not sell to patients.
- Purity : 99.00%
- CAS No.: 285985-06-0
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG4 lambda
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TGFB2
In Vitro
Lerdelimumab (10 μg/mL) inhibits all TGF-β2-induced effects. TGF-β2 stimulates transdifferentiation and contraction of the capsular bag and induces MMP-2 and -9 release of capsular bags[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 lambda2
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded Lerdelimumab on ProA biosensor, can bind TGF beta 2/TGFB2 Protein, Human (HEK293, HY-P7119) with an affinity constant of 1.927E-09 M as determined in BLI assay.
Chemical Information
-
CAS No. 285985-06-0
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Lerdelimumab]
-
Synonyms
CAT-152
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Mead AL, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3394-401. [Content Brief]
[2]. Wormstone IM, et al. TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lerdelimumab Related Classifications
HY-P99695 Related Classifications
Powered by Bioz